Impact of Albumin-bilirubin (ALBI) score on the Prognostic Significance of Patients with Heart Failure: A Retrospective Cohort Study

Su Han  
Shengjing Hospital of China Medical University

Chuanhe Wang  
Shengjing Hospital of China Medical University

Fei Tong  
Shengjing Hospital of China Medical University

Ying Li  
Shengjing Hospital of China Medical University

Zhichao Li  
Shengjing Hospital of China Medical University

Zhaoqing Sun  
Shengjing Hospital of China Medical University

Zhijun Sun  
sunzj_99@163.com  
Shengjing Hospital of China Medical University  
https://orcid.org/0000-0003-2962-5488

Research article

Keywords: Heart Failure, Liver Function, ALBI, Prognosis

DOI: https://doi.org/10.21203/rs.3.rs-125486/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Objectives Liver dysfunction is prevalent in heart failure (HF) patients and it can bring a poor prognosis. Presently, albumin-bilirubin (ALBI) score has been designed as an effective and convenient scoring system for assessing liver function, but the correlation linking ALBI and in-hospital mortality in HF patients remains unclear.

Methods and Results A total of 9749 patients with HF (from January 2013 to December 2018) was enrolled and retrospectively analyzed. The main outcome is in-hospital death. We examined and analyzed ALBI as a continuous variable as well as according to 3 categories. Following adjustment for multivariable, patients which occurred in-hospital death was remarkably elevated in Tertile 3 group (ALBI> -2.27) (OR=1.670, 95% CI: 1.231~2.265, p=0.001), relative to the other two groups (Tertile 1: <-2.59; Tertile 2: -2.59~-2.27). When ALBI was inspected as a continuous variable, the incidence of HF patients with in-hospital death will increase by 8.2%. (For ALBI score per 0.1 score increasing, OR=1.082, 95% CI: 1.052~1.113, p<0.001). ALBI score for estimating in-hospital mortality under C-statistic was 0.650 (95% CI: 0.641~0.660, p<0.001) and the cut-off value of ALBI score was -2.32 with a specificity of 0.630 and a sensitivity of 0.632. Moreover, ALBI score can enhance the estimation potential of NT-proBNP (NT-proBNP+ALBI vs NT-proBNP: C-statistic: z=1.990, p=0.0467; net reclassification improvement=0.4012, p<0.001; integrated discrimination improvement= 0.0082, p<0.001).

Conclusions In patients with HF, ALBI score was an independent prognosticator of in-hospital death. The predictive significance of NT-proBNP +ALBI was superior to NT-proBNP, and ALBI score can enhance the estimation potential of NT-proBNP.

Introduction

Heart failure (HF) patients usually suffer poor quality of life and dismal prognosis. In China, the age of heart failure onset has increased year by year, but the mortality rate of heart failure has not decreased significantly. Therefore, how to identify high-risk HF patients and actively improve their prognosis have become important issues in aging societies. It is growingly becoming clear that HF is not a single-organ disease; numerous organs other than the myocardium constituting the kidney, the lung, and gastrointestinal systems play a role and interact with each other. Besides, it has been reported that liver dysfunction is prevalent in HF patients. This is the result of high metabolic activity associated with a high oxygen demand and anatomical location near the heart associated with a high central venous pressure. Previous studies have confirmed that liver dysfunction can lead to a dismal prognosis in HF patients, but they mostly measured bilirubin, albumin, alanine aminotransferase, etc. In addition to conventional measures of liver function, a new approach, the albumin-bilirubin (ALBI) score, was developed as an important strategy to examine liver function. Previous studies have confirmed that the ALBI score is related to the patient fluid overload and adverse events after discharge from the hospital, but there are no related studies of in-hospital events.
In our study, we inspected whether ALBI score is a significant clinical factor to estimate in-hospital mortality in patients with HF. We additionally verified whether ALBI score could enhance the prognostic significance of NT-proBNP.

Methods

Study design and setting

Our retrospective study population comprised 11,556 consecutively patients aged > 18 years with HF as the main diagnosis on admission from ShengJing Hospital of China Medical University located in the northeastern part of China (from January 2013 to December 2018). HF was defined based on the modified Framingham criteria. We used a uniform questionnaire to collect clinical, as well as the procedural data of all the subjects. We employed the \((\log_{10} \text{bilirubin [umol/L]} * 0.66) + (\text{albumin [g/L]} * -0.085)\) formula to compute the ALBI score according to the serum albumin and total bilirubin levels at baseline. We collected samples of the venous blood from all the subjects on admission and kept them in standard tubes. Serum albumin and total bilirubin were assayed using completely automated enhanced immunone-phelometric assay on a Beckman AU 5800 analyzer (Beckman Coulter, USA). The standard ranges for baseline albumin and total bilirubin are 35–53 g/L and 3.4–20.5 umol/L, respectively. The primary endpoint is all-cause in-hospital death.

Exclusion criteria included (1) acute myocardial infarction (492 cases); (2) chronic alcoholism (113 cases); (3) chronic kidney failure with dialysis and diagnosed liver disease on admission (460 cases); (4) prior history of cardiac transplantation (28 cases); (5) no albumin, no total bilirubin, or no NT-proBNP data (714 cases). We finally enrolled 9,749 HF subjects into the study. The mean hospitalization period was 9.8 ± 5.7 days. Figure 1 exhibits the flowchart of selecting the patients. We clustered the subjects into three study groups as per the tertile of ALBI score on hospital admission [Tertile 1: <-2.59 (n = 3250); Tertile 2: -2.59~-2.27 (n = 3250); Tertile 3: >-2.27 (n = 3249)]. This study accedes to the Helsinki Declaration. Moreover, this study was ratified by the Research Ethics Committee in the Shengjing Hospital of China Medical University. We formally obtained a written informed consent from all the subjects.

Statistical analysis

The normal distributed quantitative variables were indicated as mean ± SD and compared using the Student’s t test. However, the quantitative variables without normal distribution were indicated as median (IQR) and employed the Kruskal-Wallis H-test to compare them. The differences between categorical variables were compared by \(\chi^2\) test. When the number of variables was lower than 5, Fisher’s exact test was used to detect the differences. We performed the logistic univariate assessments to examine the prognosticators of in-hospital mortality (online supplementary appendices S1), and then enter into the multivariate logistic regression model to uncover the independent prognosticators of in-hospital mortality. We entered the variables in the univariate evaluations with \(p < 0.05\) in a multivariate assessment. ALBI score was tested in the form of continuous variable and categorical variable. The output results were
presented by ORs with correlated 95% CIs. The prognostic potential of ALBI, NT-proBNP, and NT-proBNP + ALBI was inspected using the discrimination indices as below: (1) A receiver operating characteristic (ROC) curve and the area under the curve (AUC) in connection with the in-hospital mortality were determined by MedCalc statistical software (version 18.1.1).12 (2) We got individual risk of in-hospital mortality by entering each model into a logistic regression model. The Nagelkerke-R2, as well as the Hosmer-Lemeshow (HL) test from the regression model were employed as indices of goodness-of-fit of each risk model and to examine their calibration potential.13 We additionally computed the Brier scores of ALBI score, NT-proBNP, and NT-proBNP + ALBI score. Lower Brier scores exhibited improved precision.14 (3) The absolute integrated discrimination improvement (IDI), as well as the category-free net reclassification improvement (NRI) were used to examine enhancements in risk estimation quantization of ALBI score and NT-proBNP + ALBI.15 All the statistical tests were two-sided, and the statistical significance was marked by p < 0.05. We employed the Statistical Analysis Software (SAS Institute Inc, Cary, NC) V.9.4 to conduct all the statistical analysis.

Results

General characteristics

The flowchart of patient selection was shown in Fig. 1. We finally enrolled a study cohort of 9749 HF patients. The general characteristics were indicated in Table 1. The group of tertile 3 group had markedly higher percentage proportion of males, NYHA grading IV, relative to the other two groups. The tertile 3 group additionally had an inclination towards intensifying heart rate, serum glutamate-pyruvate transaminase (SGPT), serum glutamic oxaloacetic transaminase (SGOT), cTNI, total bilirubin, creatinine, and NT-proBNP on admission. There was a distinct pattern of diminishing systolic blood pressure, albumin, low density lipoprotein (LDL), fasting blood glucose (FBG), left ventricular ejection fraction (LVEF) in the Tertile 3 group. The proportion percentage of coronary heart disease (CHD), Hypertension, atrial fibrillation (AF) and diabetes mellitus (DM) were markedly lower in the group of tertile 3. Moreover, the tertile 3 group depicted the inclination of an elevated in-hospital mortality (6.1% vs 2.1% and 2.4%, p < 0.001) (Table 1).
Table 1
Baseline characteristics of the population by tertile of ALBI, median (IQR), or N (%), or means ± SD

| Variable               | Overall (n = 9749) | Tertile1 ALBI< -2.59 (n = 3250) | Tertile2 ALBI -2.59~ -2.27 (n = 3250) | Tertile3 ALBI> -2.27 (n = 3249) | P value |
|------------------------|-------------------|---------------------------------|---------------------------------------|---------------------------------|---------|
| Age (years)            | 69.1 ± 13.6       | 67.9 ± 12.8                     | 70.2 ± 13.1                           | 69.4 ± 14.6                     | < 0.001 |
| Male [n (%)]           | 5158 (52.9)       | 1650 (50.8)                     | 1731 (53.3)                           | 1777 (54.7)                     | 0.006   |
| NYHA grading [n (%)]   |                   |                                 |                                       |                                 | < 0.001 |
|                        | 1954 (20.0)       | 988 (30.4)                      | 637 (19.6)                            | 329 (10.1)                      |
|                        | 4207 (43.2)       | 1434 (44.1)                     | 1428 (43.9)                           | 1345 (41.4)                     |
|                        | 3588 (36.8)       | 828 (25.5)                      | 1185 (36.5)                           | 1575 (48.5)                     |
| Heart rate on admission, bpm | 87.7 ± 22.3       | 85.0 ± 21.0                     | 87.6 ± 22.4                           | 90.5 ± 23.2                     | < 0.001 |
| SBP on admission, mmHg | 135.2 ± 22.7      | 136.1 ± 21.0                    | 135.9 ± 22.7                          | 133.5 ± 24.1                    | < 0.001 |
| SGPT, U/L              | 25.5 ± 11.9       | 25.5 ± 11.0                     | 25.2 ± 11.9                           | 26.0 ± 12.7                     | 0.046   |
| SGOT, U/L              | 31 (26,35)        | 34 (23,34)                      | 31 (24,35)                            | 33 (28,37)                      | < 0.001 |
| Albumin, g/L           | 37.1 ± 4.5        | 41.3 ± 2.5                      | 37.4 ± 2.0                            | 32.6 ± 3.5                      | < 0.001 |
| TBIL, umol/L           | 16.2 ± 12.1       | 12.7 ± 6.8                      | 15.2 ± 8.7                            | 20.6 ± 16.9                     | < 0.001 |
| LDL, mmol/L            | 2.52 ± 0.91       | 2.70 ± 0.94                     | 2.52 ± 0.85                           | 2.36 ± 0.92                     | < 0.001 |
| Creatinine, mg/dl      | 1.07 ± 0.51       | 1.01 ± 0.45                     | 1.06 ± 0.50                           | 1.16 ± 0.56                     | < 0.001 |
| Haemoglobin, g/L       | 127.6 ± 21.9      | 132.0 ± 19.6                    | 128.1 ± 21.0                          | 122.8 ± 24.1                    | < 0.001 |
| Serum Na, mmol/L       | 138.9 ± 3.9       | 139.5 ± 3.3                     | 139.2 ± 3.6                           | 137.9 ± 4.5                     | < 0.001 |
| FBG, mmol/L            | 6.5 ± 1.6         | 6.6 ± 1.7                       | 6.5 ± 1.4                             | 6.4 ± 1.6                       | < 0.001 |

*SBP, systolic blood pressure; SGPT, serum glutamate-pyruvate transaminase; SGOT, serum glutamic oxaloacetic transaminase; TBIL, total bilirubin; LDL, Low Density Lipoprotein; FBG, fasting blood glucose; cTNI, cardiac troponin I; LVEF, left ventricular ejection fraction; CHD, coronary heart disease; AF, atrial fibrillation; DM, diabetes mellitus
| Variable          | Overall (n = 9749) | Tertile1 ALBI<−2.59 (n = 3250) | Tertile2 ALBI − 2.59~−2.27 (n = 3250) | Tertile3 ALBI>−2.27 (n = 3249) | P value |
|-------------------|-------------------|-------------------------------|---------------------------------------|--------------------------------|---------|
| cTNI, ng/ml       | 0.04 (0.01, 0.28) | 0.03 (0.01, 0.15)             | 0.04 (0.01, 0.31)                     | 0.06 (0.02, 0.35)              | < 0.001 |
| NT-proBNP, pg/ml  | 2538(986, 5850)   | 1376(570, 3284)               | 2492(1066, 5419)                      | 5186(1987, 9085)               | < 0.001 |
| LVEF, %           | 48.7 ± 11.3       | 50.4 ± 11.0                   | 48.9 ± 11.3                           | 46.9 ± 11.3                    | < 0.001 |
| Accompanies, n (%)|                   |                               |                                       |                               |         |
| CHD               | 6282(64.4)        | 2184(67.2)                    | 2129(65.5)                            | 1969(60.6)                     | < 0.001 |
| Hypertension      | 5948(61.0)        | 2149(63.8)                    | 2129(63.4)                            | 1860(55.8)                     | < 0.001 |
| AF                | 3086(31.7)        | 1091(33.6)                    | 1094(33.7)                            | 901(27.7)                      | < 0.001 |
| DM                | 3118(32.0)        | 1070(32.9)                    | 1023(31.5)                            | 1025(31.5)                     | 0.371   |
| Smoking [n (%)]   | 2664(27.3)        | 919(28.3)                     | 855(26.3)                             | 890(27.4)                      | 0.203   |
| In-hospital       | 343(3.5)          | 67(2.1)                       | 78(2.4)                               | 198(6.1)                       | < 0.001 |
| mortality         |                   |                               |                                       |                               |         |

*SBP, systolic blood pressure; SGPT, serum glutamate-pyruvate transaminase; SGOT, serum glutamic oxaloacetic transaminase; TBIL, total bilirubin; LDL, Low Density Lipoprotein; FBG, fasting blood glucose; cTNI, cardiac troponin I; LVEF, left ventricular ejection fraction; CHD, coronary heart disease; AF, atrial fibrillation; DM, diabetes mellitus

**Ability of ALBI score in prognosis estimation**

Numerous variables had remarkable influences on in-hospital mortality through the univariate assessment supplemented online in Appendix S1: ALBI score, age, NYHA grading, heart rate on admission, systolic blood pressure on admission, SGPT, SGOT, creatinine, haemoglobin, Serum Na, FBG, cTNI, NT-proBNP, LVEF, and the history of CHD, hypertension, AF, DM (online supplementary appendices S1).

The univariate assessment indicated that the ALBI score was linked to the in-hospital mortality (OR = 1.135, 95%CI:1.108 ~ 1.163, p < 0.001, for per 0.1 score increase) (Table 2). Following covariate adjustments, the association remained present: the risk of in-hospital mortality increased by 8.2% for per 0.1 increase in ALBI score (OR = 1.082, 95% CI:1.052 ~ 1.113, p < 0.001) (Table 2).
Table 2  
Effects of multiple variables on clinical outcomes in univariate and multivariate analysis

|                         | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|
|                         | OR      | 95% CI               | P value | OR      | 95% CI               | P value |
| NT-proBNP per 100 pg/ml increase | 1.007   | 1.006 to 1.008       | <0.001  |         |                      |         |
| ALBI as a continuous variable |         |                      |         |         |                      |         |
| ALBI, per 0.1 score increase | 1.135   | 1.108 to 1.163       | <0.001  | 1.082   | 1.052 to 1.113       | <0.001  |
| ALBI as a categories variable |         |                      |         |         |                      |         |
| Tertile 1               | Reference | Reference             |         |         |                      |         |
| Tertile 2               | 1.167    | 0.839 to 1.624       | 0.358   | 0.862   | 0.613 to 1.214       | 0.397   |
| Tertile 3               | 3.082    | 2.326 to 4.084       | <0.001  | 1.670   | 1.231 to 2.265       | 0.001   |

*Adjusted for age, NYHA grading, heart rate on admission, SBP on admission, SGPT, SGOT, creatinine, haemoglobin, serum Na, FBG, cTNI, LVEF, CHD, hypertension, AF, DM, smoking

Upon categorization into 3 groups, the ALBI score still significantly predicted incidence of in-hospital death (Table 2). Under the univariate assessments, the Tertile 3 group exhibited a markedly elevated risk of in-hospital mortality contrasted with the Tertile 1 and 2 groups (OR = 3.082, 95% CI 2.326 ~ 4.084, p < 0.001) (Table 2). After adjusting for covariates, the group with the highest incidence of in-hospital mortality was still the Tertile 3 (OR = 1.670, 95% CI:1.231 ~ 2.265, p = 0.001) (Table 2).

The prediction significance of ALBI, NT-proBNP, and NT-proBNP + ALBI was assessed by C-statistic, which result were 0.650 (95% CI: 0.641 ~ 0.660), 0.652 (95% CI:0.642 ~ 0.661), and 0.681 (95% CI:0.672 ~ 0.690) (Fig. 2 and Table 3), separately. The cut-off value for ALBI score was - 2.32 with a sensitivity of 0.632 and a specificity of 0.630.
### Table 3
NT-proBNP, NT-proBNP + ALBI and ALBI performance for the prognosis prediction

| NT-proBNP | Discrimination | Calibration | Precision |
|-----------|----------------|-------------|-----------|
|           | C-statistic    | SE          | P value   | 95% CI   | HL p value | R²   | Brier score |
|           | 0.652          | 0.0157      | < 0.001   | 0.642 to 0.661 | 0.007 | 0.033 | 0.0336 |
| NT-proBNP + ALBI | 0.681          | 0.0157      | < 0.001   | 0.672 to 0.690 | < 0.001 | 0.039 | 0.0334 |
| ALBI      | 0.650          | 0.0162      | < 0.001   | 0.641 to 0.660 | 0.012 | 0.038 | 0.0335 |

### Improvement of the prognostic significance of ALBI + NT-proBNP

The HL p value, Nagelkerke-R², as well as Brier score the of ALBI + NT-proBNP were Significantly better than the other two groups (Table 3). The novel model in which the NT-proBNP was incorporated with ALBI can enhance the estimation significance. The prognostic value of NT-proBNP + ALBI was superior to that of NT-proBNP (C- statistic: z = 1.990, p = 0.0467; IDI = 0.0082, p < 0.001; NRI = 0.4012, p < 0.001) (Table 4).

### Table 4
Comparisons of the predictive performance of NT-proBNP, NT-proBNP + ALBI and ALBI for the prognosis prediction

| ALBI vs NT-proBNP | z for C-statistic | P for C-statistic | NRI | P for NRI | IDI | P for IDI |
|-------------------|-------------------|------------------|-----|-----------|-----|-----------|
|                   | 0.0938            | 0.9253           | 0.0518 | 0.3461 | 0.0018 | 0.4204 |
| ALBI + NT-proBNP vs NT-proBNP | 1.990          | 0.0467           | 0.4012 | < 0.001 | 0.0082 | < 0.001 |
| ALBI + NT-proBNP vs ALBI | 4.362          | < 0.001          | 0.4054 | < 0.001 | 0.0063 | 0.0001 |

### Discussion

The present study inspected the correlation linking the ALBI score and in-hospital mortality in HF patients. We elucidated that: (1) the ALBI score is an independent prognosticator of in-hospital death; (2) the predictive significance of NT-proBNP + ALBI is superior to NT-proBNP, and ALBI score can enhance the estimation potential of the initial NT-proBNP model in patients with HF.

Various studies have assessed the prognostic clinical significance using distinct liver function test (LFT) indices in HF patients. Post-hoc evaluation of the EVEREST study posited that the low baseline albumin and increased bilirubin, were associated with clinical outcome.\textsuperscript{16} PROTECT study found the escalating AST and ALT on day 3, and diminishing albumin on day 4 are independent predictors of 180-day
outcomes of HF patients. More and more studies have realized that the reserve of liver function is not only a single parameter, but also other factors with joint variables exist, so at present, the joint scoring system is mostly used to judge the liver function reserve of patients, including Child-Pugh classification (CP), MELD score and ALBI score. The CP constitutes some weaknesses, such as subjective parameters (ascites and encephalopathy), and interrelated indices (serum albumin and ascites), and it was not statistically established. MELD score system is an independent prediction index of adverse outcomes in HF patients. However, for the ALBI score, there is limited research. To our best knowledge, no study has explored the prediction value of the ALBI score for the in-hospital mortality in HF patients. In our study, we elucidated that the ALBI score was correlated with in-hospital mortality for HF patients. With ALBI score as a continuous variable, we established that the risk of in-hospital mortality increased by 8.2% per 0.1 score increase in ALBI (OR = 1.082, 95% CI: 1.052 ~ 1.113, p < 0.001). As illustrated in Table 2, ALBI score was still associated with in-hospital mortality when treated as a categorical variable (OR = 1.670, 95% CI: 1.231 ~ 2.265, p = 0.001). Previous reports have verified that NT-proBNP is linked to adverse events in HF patients, whether in hospital or discharged. NT-proBNP is excreted by the kidney, and its circulating concentrations must be interpreted based on renal clearance. The patients with HF usually suffer a renal dysfunction, NT-proBNP may be abnormally elevated in this group of patients, which limits its clinical utility in this setting. The ALBI score has no such restrictions, compared to the classic indicator NT-proBNP, ALBI score has not less than its predictive value (C-statistic: z = 0.0938, p = 0.9253). Furthermore, ALBI score can enhance the predictive significance of NT-proBNP (C-statistic: z = 1.990, p = 0.0467; IDI = 0.0082, p < 0.001; NRI = 0.4012, p < 0.001).

Although the detailed pathophysiological correlation linking liver dysfunction to HF requires detailed assessments, numerous likely mechanisms can be postulated. Severe congestive HF is linked to two different kinds of liver conditions: acute hepatocellular necrosis that is caused by compromised blood supply as well as jaundice, which is correlated with the passive congestion. Compromised blood supply due to diminished cardiac output has a connection with acute hepatocellular necrosis with distinct escalations in serum aminotransferases. The passive hepatic congestion is associated with the elevated central venous pressure, resulting in increments in the levels of liver enzymes, as well as indirect and direct circulating bilirubin. Kato et al studied liver metabolism of HF in a rat model and established that congestive HF is linked to atypical metabolism in tissues adjacent to the heart. In the congestive HF rats, hepatic protein blood concentrations, including albumin, transferrin, retinol-binding protein, and transthyretin were reduced and correlated with elevated levels of circulatory proinflammatory cytokines (TNF-α and IL-1β). Because of heart which has poor capacity of energy storage, and it need a continuous energy supply, all the above studies support the possibility that liver dysfunction may lead to impaired cardiac energy supply, which may lead to a poor prognosis. The ALBI score was initially created from Japanese hepatocellular carcinoma (HCC) patients to estimate the extent of liver dysfunction. However, it has also been widely used in patients without HCC. Notably, one study posited that the ALBI score was related to liver function as assayed by the indocyanine green injection test. These results support that the ALBI score can reflect residual liver function reserve, even in patients without HCC.
Our findings have some clinical significance. First, observing ALBI in HF patients may be significant in establishing HF patients with elevated risk of in-hospital adverse events. Moreover, the predictive significance of ALBI score is as good as that achieved by NT-proBNP. If the patient is combined with kidney dysfunction, which NT-proBNP is limited for clinical utility, ALBI score may be useful for this setting. At last, if we consider the patient's cardiac function and liver dysfunction together, it may bring some help to clinicians.

The current study has several limitations. First, it constituted a retrospective and observational design; therefore, possible confounders and selection bias were not absolutely adjusted. Secondly, we did not examine all the LFTs individually, as some biosignatures were missing in our dataset. For example, in the FINRISK study, moderate to high levels of serum $\gamma$-glutamyltransferase were markedly correlated with incident HF among 38076 people.\textsuperscript{38} In addition, higher alkaline phosphatase was linked to a dismal prognosis in patients with AHF.\textsuperscript{39} Thirdly, the study population constituted part of the Asians, therefore, the results of the study may need to be further serious in other populations.

**Conclusion**

In patients with HF, ALBI score was an independent prognosticator of in-hospital death. The predictive significance of NT-proBNP + ALBI was superior to NT-proBNP, and ALBI score can enhance the estimation potential of NT-proBNP.

**Declarations**

**Ethics approval and consent to participate:** IRB information: Shengjing Hospital of China Medical University\textsuperscript{\textcopyright} 2019PS594K

Consent for publication: Not applicable

**Availability of data and materials:** The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests:** The authors declare that they have no competing interests.

**Funding:** Not applicable

**Authors’ contributions:** SH designed of the work and and was a major contributor in writing the manuscript. CHW, FT, YL collected and applied of statistical techniques to analyze study data. ZCL, ZQS managed activities to annotate (produce metadata), scrub data and maintain research data for initial use and later reuse. ZJS formulated of overarching research goals and aims, reviewed and edited the manuscript. All authors read and approved the final manuscript.

**Acknowledgements:** All of the investigators and staff members were gratefully acknowledged. Thanks for all the enthusiastic participants.
References

1. Chandra A, Vaduganathan M, Lewis E, Claggett B, Rizkala A, Wang W, et al. Health-Related Quality of Life in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Trial. JACC-Heart Fail. 2019;7(10):862-74.

2. Ma LY, Chen WW, Gao RL, Liu LS, Zhu ML, Wang YJ, et al. China cardiovascular diseases report 2018: an updated summary. J Geriatr Cardiol, 2020, 17: 1-8.

3. Harjola V, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca H, Chioncel O, et al. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). EUR J HEART FAIL. 2017;19(7):821-36.

4. Peng J, Xiao X, Hu M, Zhang X. Interaction between gut microbiome and cardiovascular disease. LIFE SCI. 2018;214:153-57.

5. Rangaswami J, Bhalla V, Blair J, Chang T, Costa S, Lentine K, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation. 2019;139(16):e840-e78.

6. Samsky M, Patel C, DeWald T, Smith A, Felker G, Rogers J, et al. Cardiohepatic interactions in heart failure: an overview and clinical implications. J AM COLL CARDIOL. 2013;61(24):2397-405.

7. Laribi S, Mebazaa A. Cardiohepatic syndrome: liver injury in decompensated heart failure. Curr Heart Fail Rep. 2014;11(3):236-40.

8. Vasconcelos L, de Almeida E, Bachur L. Clinical evaluation and hepatic laboratory assessment in individuals with congestive heart failure. ARQ BRAS CARDIOL. 2007;88(5):590-5.

9. Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves H, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J CLIN ONCOL. 2015;33(6):550-8.

10. Matsue Y, Kagiyama N, Yamaguchi T, Kuroda S, Okumura T, Kida K, et al. Clinical and Prognostic Values of ALBI Score in Patients with Acute Heart Failure. HEART LUNG CIRC. 2019.

11. McKee P, Castelli W, McNamara P, Kannel W. The natural history of congestive heart failure: the Framingham study. NEW ENGL J MED. 1971;285(26):1441-6.

12. DeLong E, DeLong D, Clarke-Pearson D. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-45.

13. Lemeshow S, Hosmer D. A review of goodness of fit statistics for use in the development of logistic regression models. AM J EPIDEMIOL. 1982;115(1):92-106.

14. Redelmeier D, Bloch D, Hickam D. Assessing predictive accuracy: how to compare Brier scores. J CLIN EPIDEMIOL. 1991;44(11):1141-6.

15. Pencina M, D'Agostino R, D'Agostino R, Vasan R. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Statistics in
medicine.2008;27(2):157-72; discussion 207-12.

16. Ambrosy A, Vaduganathan M, Huffman M, Khan S, Kwasny M, Fought A, et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. EUR J HEART FAIL. 2012;14(3):302-11.

17. Biegus J, Hillege H, Postmus D, Valente M, Bloomfield D, Cleland J, et al. Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. EUR J HEART FAIL. 2016;18(7):830-9.

18. Pugh R, Murray-Lyon I, Dawson J, Pietroni M, Williams R. Transection of the oesophagus for bleeding oesophageal varices. BRIT J SURG. 1973;60(8):646-9.

19. Heuman D, Mihas A, Habib A, Gilles H, Stravitz R, Sanyal A, et al. MELD-XI: a rational approach to "sickest first" liver transplantation in cirrhotic patients requiring anticoagulant therapy. LIVER TRANSPLANT. 2007;13(1):30-7.

20. Hiraoka A, Kumada T, Michitaka K, Kudo M. Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. LIVER CANCER. 2019;8(5):312-25.

21. Kim M, Kato T, Farr M, Wu C, Givens R, Collado E, et al. Hepatic dysfunction in ambulatory patients with heart failure: application of the MELD scoring system for outcome prediction. J AM COLL CARDIOL. 2013;61(22):2253-61.

22. Abe S, Yoshihisa A, Takiguchi M, Shimizu T, Nakamura Y, Yamauchi H, et al. Liver dysfunction assessed by model for end-stage liver disease excluding INR (MELD-XI) scoring system predicts adverse prognosis in heart failure. PLOS ONE. 2014;9(6):e100618.

23. Inohara T, Kohsaka S, Shiraishi Y, Goda A, Sawano M, Yagawa M, et al. Prognostic impact of renal and hepatic dysfunction based on the MELD-XI score in patients with acute heart failure. INT J CARDIOL. 2014;176(3):571-3.

24. Biegus J, Zymiński R, Sokolski M, Siwołowski P, Gajewski P, Nawrocka-Millward S, et al. Impaired hepato-renal function defined by the MELD XI score as prognosticator in acute heart failure. EUR J HEART FAIL. 2016;18(12):1518-21.

25. Grodin J, Gallup D, Anstrom K, Felker G, Chen H, Tang W. Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from DOSE-AHF and ROSE-AHF). AM J CARDIOL. 2017;119(12):2003-09.

26. Aimo A, Januzzi J, Mueller C, Mirò O, Pascual Figal D, Jacob J, et al. Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. INT J CARDIOL. 2019;293:137-42.

27. Scrutinio D, Ammirati E, Guida P, Passantino A, Raimondo R, Guida V, et al. Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score. INT J CARDIOL. 2013;168(3):2120-6.
28. Zoair A, Abdel-Hafez M, Mawlana W, Sweylam M. Serum levels of N-terminal-pro B-type natriuretic peptide as a diagnostic marker for left ventricular dysfunction in children with end-stage renal disease on hemodialysis. Saudi J Kidney Dis Transpl. 2016;27(6):1114-22.

29. Artunc F, Mueller C, Breidthardt T, Twerenbold R, Rettig I, Usta E, et al. Comparison of the diagnostic performance of three natriuretic peptides in hemodialysis patients: which is the appropriate biomarker? KIDNEY BLOOD PRESS R. 2012;36(1):172-81.

30. Giallourakis C, Rosenberg P, Friedman L. The liver in heart failure. CLIN LIVER DIS. 2002;6(4):947-67.

31. Alvarez A, Mukherjee D. Liver abnormalities in cardiac diseases and heart failure. Int J Angiol. 2011;20(3):135-42.

32. Kato T, Niizuma S, Inuzuka Y, Kawashima T, Okuda J, Kawamoto A, et al. Analysis of liver metabolism in a rat model of heart failure. INT J CARDIOL. 2012;161:130–6.

33. Shao L, Han B, An S, Ma J, Guo X, Romeiro F, et al. Albumin-to-bilirubin score for assessing the in-hospital death in cirrhosis. Transl Gastroenterol Hepatol. 2017;2:88.

34. Lei Q, Zhang Y, Ke C, Yan C, Huang P, Shen H, et al. Value of the albumin-bilirubin score in the evaluation of hepatitis B virus-related acute-on-chronic liver failure, liver cirrhosis, and hepatocellular carcinoma. EXP THER MED. 2018;15(3):3074-79.

35. Xavier S, Vilas-Boas R, Boal Carvalho P, Magalhães J, Marinho C, Cotter J. Assessment of prognostic performance of Albumin-Bilirubin, Child-Pugh, and Model for End-stage Liver Disease scores in patients with liver cirrhosis complicated with acute upper gastrointestinal bleeding. EUR J GASTROEN HEPAT. 2018;30(6):652-58.

36. Chen B, Lin S. Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure. MEDICINE. 2017;96(24):e7142.

37. Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itobayashi E, et al. Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. LIVER CANCER. 2017;6(3):204-15.

38. Wang Y, Tuomilehto J, Jousilahti P, Salomaa V, Li B, Antikainen R, et al. Serum γ-glutamyltransferase and the risk of heart failure in men and women in Finland. Heart. 2013;99(3):163-7.

39. Nikolaou M, Parissis J, Yilmaz M, Seronde M, Kivikko M, Laribi S, et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. EUR HEART J. 2013;34(10):742-9.

Figures
January 2013 to December 2018
Patients with Main Diagnosis of HF
(n=11556)

Major Exclusions (total=1093)
- acute myocardial infarction (n=492)
- excessive alcohol consumption (n=113)
- diagnosed liver disease and chronic kidney failure with dialysis on admission (n=460)
- history of cardiac transplantation (n=28)

Total Recruited
(n=10079)

NOT ASSESSED FOR ANALYSIS (n=714)
- No albumin, no total bilirubin, or no NT-proBNP data (n=714)

DATA AVAILABLE FOR ANALYSIS (n=9749)
- Tertile 1 (n=3250)
- Tertile 2 (n=3250)
- Tertile 3 (n=3249)

Figure 1
Flowchart of patient selection
January 2013 to December 2018
Patients with Main Diagnosis of HF
(n=11556)

Major Exclusions (total=1093)
- acute myocardial infarction (n=492)
- excessive alcohol consumption (n=113)
- diagnosed liver disease and chronic kidney failure with dialysis on admission (n=460)
- history of cardiac transplantation (n=28)

Total Recruited
(n=10079)

NOT ASSESSED FOR ANALYSIS (n=714)
- No albumin, no total bilirubin, or no NT-proBNP data (n=714)

DATA AVAILABLE FOR ANALYSIS (n=9749)
- Tertile 1 (n=3250)
- Tertile 2 (n=3250)
- Tertile 3 (n=3249)

Figure 1
Flowchart of patient selection
Figure 2

Receiver operating characteristic curves of ALBI, NT-proBNP and ALBI +NT-proBNP for in-hospital death prediction.
Figure 2

Receiver operating characteristic curves of ALBI, NT-proBNP and ALBI +NT-proBNP for in-hospital death prediction.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- AppendixS1.docx
- AppendixS1.docx